<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35788744</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.</ArticleTitle><Pagination><StartPage>4581</StartPage><EndPage>4603</EndPage><MedlinePgn>4581-4603</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11237-1</ELocationID><Abstract><AbstractText>The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects people who suffer from Multiple Sclerosis, evaluating the risk they have of suffering an infection by this virus, according to the therapy to which they are subjected as well as the immune response of these patients both to infection and vaccines and the neurological consequences that the virus can have in the long term. The results regarding the increased risk of infection due to treatment are contradictory. B-cell depletion therapies may cause patients to have a lower probability of generating a detectable neutralizing antibody titer. However, more studies are needed to help understand how this virus works, paying special attention to long COVID and the neurological symptoms that it causes.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mu&#xf1;oz-Jurado</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7908-861X</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Faculty of Veterinary Medicine, University of Cordoba, Campus of Rabanales, 14071, Cordoba, Spain. b22mujua@uco.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Escribano</LastName><ForeName>Bego&#xf1;a M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Faculty of Veterinary Medicine, University of Cordoba, Campus of Rabanales, 14071, Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ag&#xfc;era</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Service, Reina Sofia University Hospital, Cordoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caballero-Villarraso</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Faculty of Medicine and Nursing, University of Cordoba, Av. Menendez Pidal, 14004, Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Analysis Service, Reina Sof&#xed;a University Hospital, Cordoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galv&#xe1;n</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Faculty of Medicine and Nursing, University of Cordoba, Av. Menendez Pidal, 14004, Cordoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xfa;nez</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4493-7087</Identifier><AffiliationInfo><Affiliation>Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain. itunez@uco.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Faculty of Medicine and Nursing, University of Cordoba, Av. Menendez Pidal, 14004, Cordoba, Spain. itunez@uco.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cooperative Research Thematic Excellent Network on Brain Stimulation (REDESTIM), Madrid, Spain. itunez@uco.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjuvant treatments</Keyword><Keyword MajorTopicYN="N">Disease-modifying therapies</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">Multiple sclerosis</Keyword><Keyword MajorTopicYN="N">Neuro-COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>18</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35788744</ArticleId><ArticleId IdType="pmc">PMC9253265</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11237-1</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11237-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palao M, Fern&#xe1;ndez-D&#xed;az E, Gracia-Gil J, et al. Multiple sclerosis following SARS-CoV-2 infection. Mult Scler Relat Disord. 2020 doi: 10.1016/j.msard.2020.102377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102377</ArticleId><ArticleId IdType="pmc">PMC7340057</ArticleId><ArticleId IdType="pubmed">32698095</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Coronavirus Disease (COVID-19) Situation Reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. Accessed 26 May 2022</Citation></Reference><Reference><Citation>Reyes S, Cunningham A, Kalincik T, et al. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: an international consensus statement. J Neuroimmunol. 2021;357:577627. doi: 10.1016/J.JNEUROIM.2021.577627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JNEUROIM.2021.577627</ArticleId><ArticleId IdType="pmc">PMC8183006</ArticleId><ArticleId IdType="pubmed">34139567</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383:2451&#x2013;2460. doi: 10.1056/NEJMCP2009575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMCP2009575</ArticleId><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos W. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother. 2021;136:111272. doi: 10.1016/J.BIOPHA.2021.111272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BIOPHA.2021.111272</ArticleId><ArticleId IdType="pmc">PMC7802525</ArticleId><ArticleId IdType="pubmed">33486212</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano M, Ruggiero A, Squeglia F, et al. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading, and final capping. Cells. 2020;9:1267. doi: 10.3390/CELLS9051267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/CELLS9051267</ArticleId><ArticleId IdType="pmc">PMC7291026</ArticleId><ArticleId IdType="pubmed">32443810</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R, Kang A, Luo X, et al. COVID-19: current knowledge in clinical features, immunological responses, and vaccine development. FASEB J. 2021;35:1&#x2013;23. doi: 10.1096/fj.202002662R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202002662R</ArticleId><ArticleId IdType="pmc">PMC7898934</ArticleId><ArticleId IdType="pubmed">33577115</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:1&#x2013;22. doi: 10.1186/S12985-019-1182-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12985-019-1182-0</ArticleId><ArticleId IdType="pmc">PMC6537279</ArticleId><ArticleId IdType="pubmed">31133031</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J, Thone MN, Jik Y. COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2020;170:1&#x2013;25. doi: 10.1016/j.addr.2020.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.12.011</ArticleId><ArticleId IdType="pmc">PMC7759095</ArticleId><ArticleId IdType="pubmed">33359141</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020;217:e20200678. doi: 10.1084/JEM.20200678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20200678</ArticleId><ArticleId IdType="pmc">PMC7191310</ArticleId><ArticleId IdType="pubmed">32353870</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Liu S, Goraya M, et al. Host immune response to influenza A virus infection. Front Immunol. 2018;9:320. doi: 10.3389/FIMMU.2018.00320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2018.00320</ArticleId><ArticleId IdType="pmc">PMC5845129</ArticleId><ArticleId IdType="pubmed">29556226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533&#x2013;535. doi: 10.1038/S41423-020-0402-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41423-020-0402-2</ArticleId><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62&#x2013;75. doi: 10.1016/J.CYTOGFR.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CYTOGFR.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;51(5):1&#x2013;8. doi: 10.1038/s41392-020-00243-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00243-2</ArticleId><ArticleId IdType="pmc">PMC7381863</ArticleId><ArticleId IdType="pubmed">32712629</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak-Kiczmer M, Kubicka-B&#x105;czyk K, Niedziela N, et al. The course of COVID-19 infection in patients with multiple sclerosis&#x2014;the experience of one center based on the population of Upper Silesia. Mult Scler Relat Disord. 2021 doi: 10.1016/J.MSARD.2021.102984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102984</ArticleId><ArticleId IdType="pmc">PMC8080501</ArticleId><ArticleId IdType="pubmed">34000683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mado H, Adamczyk-Sowa M. Multiple sclerosis patients and COVID-19. Egypt J Neurol psychiatry Neurosurg. 2021;57:43. doi: 10.1186/S41983-021-00287-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S41983-021-00287-3</ArticleId><ArticleId IdType="pmc">PMC7985914</ArticleId><ArticleId IdType="pubmed">33776407</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeganeh-Salehpour M, Mollica A, Momtaz S, et al. Melatonin and multiple sclerosis: from plausible neuropharmacological mechanisms of action to experimental and clinical evidence. Clin Drug Investig. 2019;39:607&#x2013;624. doi: 10.1007/s40261-019-00793-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-019-00793-6</ArticleId><ArticleId IdType="pubmed">31054087</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Zhang T, Lee TH. Cellular mechanisms of melatonin: insight from neurodegenerative diseases. Biomolecules. 2020;10:1&#x2013;26. doi: 10.3390/biom10081158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10081158</ArticleId><ArticleId IdType="pmc">PMC7464852</ArticleId><ArticleId IdType="pubmed">32784556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunata M, Parlakpinar H, Acet HA. Melatonin: a review of its potential functions and effects on neurological diseases. Rev Neurol (Paris) 2020;176:148&#x2013;165. doi: 10.1016/j.neurol.2019.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.07.025</ArticleId><ArticleId IdType="pubmed">31718830</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77:184&#x2013;191. doi: 10.1001/jamaneurol.2019.3365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.3365</ArticleId><ArticleId IdType="pmc">PMC6784753</ArticleId><ArticleId IdType="pubmed">31589278</ArticleId></ArticleIdList></Reference><Reference><Citation>Broche-P&#xe9;rez Y, Jim&#xe9;nez-Morales RM, Monasterio-Ramos LO, et al. Fear of COVID-19, problems accessing medical appointments, and subjective experience of disease progression, predict anxiety and depression reactions in patients with Multiple Sclerosis. Mult Scler Relat Disord. 2021;53:103070. doi: 10.1016/J.MSARD.2021.103070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.103070</ArticleId><ArticleId IdType="pmc">PMC8170908</ArticleId><ArticleId IdType="pubmed">34119745</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi R, Rezaeimanesh N, Sahraian MA, Moghadasi AN. The possible direct correlation between cognitive impairment and fear of catching COVID-19 among patients with multiple sclerosis. Iran J Psychiatry. 2021;16:336&#x2013;342. doi: 10.18502/IJPS.V16I3.6260.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/IJPS.V16I3.6260</ArticleId><ArticleId IdType="pmc">PMC8452838</ArticleId><ArticleId IdType="pubmed">34616468</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreu-Caravaca L, Ramos-Campo D, Manonelles P, et al. Effect of COVID-19 home confinement on sleep monitorization and cardiac autonomic function in people with multiple sclerosis: a prospective cohort study. Physiol Behav. 2021;237:113392. doi: 10.1016/J.PHYSBEH.2021.113392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.PHYSBEH.2021.113392</ArticleId><ArticleId IdType="pmc">PMC9159797</ArticleId><ArticleId IdType="pubmed">33753090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramezani N, Ashtari F, Bastami EA, et al. Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population. Mult Scler Relat Disord. 2021;50:102798. doi: 10.1016/J.MSARD.2021.102798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102798</ArticleId><ArticleId IdType="pmc">PMC7982777</ArticleId><ArticleId IdType="pubmed">33571791</ArticleId></ArticleIdList></Reference><Reference><Citation>Manacorda T, Bandiera P, Terzuoli F, et al. Impact of the COVID-19 pandemic on persons with multiple sclerosis: early findings from a survey on disruptions in care and self-reported outcomes. J Health Serv Res Policy. 2021;26:189&#x2013;197. doi: 10.1177/1355819620975069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1355819620975069</ArticleId><ArticleId IdType="pmc">PMC8182334</ArticleId><ArticleId IdType="pubmed">33337256</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sofiani ME, Alyusuf EY, Alharthi S, et al. Rapid implementation of a diabetes telemedicine clinic during the coronavirus disease 2019 outbreak: our protocol, experience, and satisfaction reports in Saudi Arabia. J Diabetes Sci Technol. 2021;15:329&#x2013;338. doi: 10.1177/1932296820947094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1932296820947094</ArticleId><ArticleId IdType="pmc">PMC7925440</ArticleId><ArticleId IdType="pubmed">32762362</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez A, Sreeganga SD, Ramaprasad A. Access to healthcare during COVID-19. Int J Environ Res Public Health. 2021;18:1&#x2013;12. doi: 10.3390/IJERPH18062980.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IJERPH18062980</ArticleId><ArticleId IdType="pmc">PMC7999346</ArticleId><ArticleId IdType="pubmed">33799417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabetkish N, Rahmani A. The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view. Heal Sci Reports. 2021;4:e386. doi: 10.1002/HSR2.386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/HSR2.386</ArticleId><ArticleId IdType="pmc">PMC8485600</ArticleId><ArticleId IdType="pubmed">34622020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe R, Barlow C, Lloyd B, et al. Lifestyle, Exercise and Activity Package for People living with Progressive Multiple Sclerosis (LEAP-MS): adaptions during the COVID-19 pandemic and remote delivery for improved efficiency. Trials. 2021 doi: 10.1186/S13063-021-05245-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13063-021-05245-1</ArticleId><ArticleId IdType="pmc">PMC8050990</ArticleId><ArticleId IdType="pubmed">33863342</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaygannejad V, Mirmosayyeb O, Nehzat N, Ghajarzadeh M. Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage. Neurol Sci. 2021;42:2615&#x2013;2618. doi: 10.1007/S10072-021-05253-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10072-021-05253-8</ArticleId><ArticleId IdType="pmc">PMC8049617</ArticleId><ArticleId IdType="pubmed">33860396</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmann A, Loebermann M, Reisinger E, et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12:217&#x2013;233. doi: 10.1038/NRNEUROL.2016.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/NRNEUROL.2016.21</ArticleId><ArticleId IdType="pubmed">26943779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani M, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89:780&#x2013;789. doi: 10.1002/ANA.26028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ANA.26028</ArticleId><ArticleId IdType="pmc">PMC8013440</ArticleId><ArticleId IdType="pubmed">33480077</ArticleId></ArticleIdList></Reference><Reference><Citation>Mycko M. B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection? Neurol Neurochir Pol. 2020;54:490&#x2013;501. doi: 10.5603/PJNNS.A2020.0083.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/PJNNS.A2020.0083</ArticleId><ArticleId IdType="pubmed">33073348</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis MD, Robertson NP. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. J Neurol. 2020;267:1567&#x2013;1569. doi: 10.1007/s00415-020-09822-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09822-3</ArticleId><ArticleId IdType="pmc">PMC7163169</ArticleId><ArticleId IdType="pubmed">32303837</ArticleId></ArticleIdList></Reference><Reference><Citation>Celius E. Infections in patients with multiple sclerosis: implications for disease-modifying therapy. Acta Neurol Scand. 2017;136:34&#x2013;36. doi: 10.1111/ANE.12835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ANE.12835</ArticleId><ArticleId IdType="pubmed">29068490</ArticleId></ArticleIdList></Reference><Reference><Citation>Reder A, Centonze D, Naylor M, et al. COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs. 2021;35:317&#x2013;330. doi: 10.1007/S40263-021-00804-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S40263-021-00804-1</ArticleId><ArticleId IdType="pmc">PMC7980129</ArticleId><ArticleId IdType="pubmed">33743151</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger J, Brandstadter R, Bar-Or A. COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol neuroinflammation. 2020;7:e761. doi: 10.1212/NXI.0000000000000761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000761</ArticleId><ArticleId IdType="pmc">PMC7238896</ArticleId><ArticleId IdType="pubmed">32414755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkl M, Frascolla S, Amormino C, et al. T helper cells: the modulators of inflammation in multiple sclerosis. Cells. 2020;9:482. doi: 10.3390/CELLS9020482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/CELLS9020482</ArticleId><ArticleId IdType="pmc">PMC7072830</ArticleId><ArticleId IdType="pubmed">32093011</ArticleId></ArticleIdList></Reference><Reference><Citation>Anagnostouli M, Markoglou N, Chrousos G. Psycho-neuro-endocrino-immunologic issues in multiple sclerosis: a critical review of clinical and therapeutic implications. Hormones. 2020;19:485&#x2013;496. doi: 10.1007/s42000-020-00197-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42000-020-00197-8</ArticleId><ArticleId IdType="pubmed">32488815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold R, Rieckmann P, Chang P, Abdalla J. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol. 2005;12:649&#x2013;656. doi: 10.1111/J.1468-1331.2005.01083.X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/J.1468-1331.2005.01083.X</ArticleId><ArticleId IdType="pubmed">16053475</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith T, Kister I. Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies. Curr Neurol Neurosci Rep. 2021;21:36. doi: 10.1007/S11910-021-01117-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S11910-021-01117-Y</ArticleId><ArticleId IdType="pmc">PMC8132488</ArticleId><ArticleId IdType="pubmed">34009478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J, Tejada-Simon M, Rivera V, et al. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler. 2002;8:237&#x2013;242. doi: 10.1191/1352458502MS794OA.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1352458502MS794OA</ArticleId><ArticleId IdType="pubmed">12120696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hada M, Mosholder AD, Leishear K, Perez-Vilar S. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol Sci. 2022;43:1557&#x2013;1567. doi: 10.1007/S10072-021-05846-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10072-021-05846-3</ArticleId><ArticleId IdType="pmc">PMC8743352</ArticleId><ArticleId IdType="pubmed">35006442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifian-Dorche M, Sahraian M, Fadda G, et al. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review. Mult Scler Relat Disord. 2021;50:102800. doi: 10.1016/J.MSARD.2021.102800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102800</ArticleId><ArticleId IdType="pmc">PMC7845520</ArticleId><ArticleId IdType="pubmed">33578206</ArticleId></ArticleIdList></Reference><Reference><Citation>Zrzavy T, Wimmer I, Rommer PS, Berger T. Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. Eur J Neurol. 2021;28:3503&#x2013;3516. doi: 10.1111/ENE.14578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ENE.14578</ArticleId><ArticleId IdType="pmc">PMC7675490</ArticleId><ArticleId IdType="pubmed">33090599</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrotta E, Kister I, Charvet L, et al. COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. Neurol Neuroimmunol Neuroinflammation. 2020 doi: 10.1212/NXI.0000000000000835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000835</ArticleId><ArticleId IdType="pmc">PMC7357412</ArticleId><ArticleId IdType="pubmed">32646885</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Jumah M, Abulaban A, Aggad H, et al. Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia. Mult Scler Relat Disord. 2021;51:102925. doi: 10.1016/J.MSARD.2021.102925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102925</ArticleId><ArticleId IdType="pmc">PMC7992311</ArticleId><ArticleId IdType="pubmed">33857897</ArticleId></ArticleIdList></Reference><Reference><Citation>Alborghetti M, Bellucci G, Gentile A, et al. Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. Curr Neuropharmacol. 2021;20:107&#x2013;125. doi: 10.2174/1570159X19666210330094017.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X19666210330094017</ArticleId><ArticleId IdType="pmc">PMC9199540</ArticleId><ArticleId IdType="pubmed">33784961</ArticleId></ArticleIdList></Reference><Reference><Citation>Luetic G, Menichini M, Burgos M, et al. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: first national case series. Mult Scler Relat Disord. 2021;53:103049. doi: 10.1016/J.MSARD.2021.103049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.103049</ArticleId><ArticleId IdType="pmc">PMC8164731</ArticleId><ArticleId IdType="pubmed">34130197</ArticleId></ArticleIdList></Reference><Reference><Citation>Golshani M, Hrd&#xfd; J. Multiple sclerosis patients and disease modifying therapies: impact on immune responses against COVID-19 and SARS-CoV-2 vaccination. Vaccines. 2022 doi: 10.3390/VACCINES10020279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/VACCINES10020279</ArticleId><ArticleId IdType="pmc">PMC8876554</ArticleId><ArticleId IdType="pubmed">35214735</ArticleId></ArticleIdList></Reference><Reference><Citation>Laroni A, Schiavetti I, Sormani M, Uccelli A. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult Scler. 2020;27:2126&#x2013;2136. doi: 10.1177/1352458520971817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520971817</ArticleId><ArticleId IdType="pubmed">33205695</ArticleId></ArticleIdList></Reference><Reference><Citation>Maghzi AH, Houtchens MK, Preziosa P, et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020;267:2790&#x2013;2796. doi: 10.1007/S00415-020-09944-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-020-09944-8</ArticleId><ArticleId IdType="pmc">PMC7268971</ArticleId><ArticleId IdType="pubmed">32494856</ArticleId></ArticleIdList></Reference><Reference><Citation>Yetkin M, Yetkin N, Akcakoyunlu M, Mirza M. Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide. Neurol Sci. 2021;42:1661&#x2013;1664. doi: 10.1007/S10072-021-05097-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10072-021-05097-2</ArticleId><ArticleId IdType="pmc">PMC7856853</ArticleId><ArticleId IdType="pubmed">33534122</ArticleId></ArticleIdList></Reference><Reference><Citation>Capone F, Motolese F, Luce T, et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis: a case report and literature review. Mult Scler Relat Disord. 2021;48:102734. doi: 10.1016/J.MSARD.2020.102734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102734</ArticleId><ArticleId IdType="pmc">PMC7836732</ArticleId><ArticleId IdType="pubmed">33429305</ArticleId></ArticleIdList></Reference><Reference><Citation>Timpani C, Rybalka E. Calming the (Cytokine) storm: dimethyl fumarate as a therapeutic candidate for COVID-19. Pharmaceuticals. 2020;14:1&#x2013;15. doi: 10.3390/PH14010015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/PH14010015</ArticleId><ArticleId IdType="pmc">PMC7824470</ArticleId><ArticleId IdType="pubmed">33375288</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31:233&#x2013;243. doi: 10.1097/WCO.0000000000000561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000561</ArticleId><ArticleId IdType="pubmed">29634596</ArticleId></ArticleIdList></Reference><Reference><Citation>Capone F, Ferraro E, Motolese F, Di Lazzaro V. COVID-19 in multiple sclerosis patients treated with dimethyl fumarate. J Neurol. 2021;268:3132&#x2013;3134. doi: 10.1007/S00415-021-10446-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-021-10446-4</ArticleId><ArticleId IdType="pmc">PMC7896828</ArticleId><ArticleId IdType="pubmed">33611610</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoy K, Mariotte D, Defer G, et al. Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring. Front Immunol. 2020;11:549842. doi: 10.3389/FIMMU.2020.549842/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2020.549842/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC7541830</ArticleId><ArticleId IdType="pubmed">33072089</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133:1380&#x2013;1390. doi: 10.1016/J.AMJMED.2020.05.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AMJMED.2020.05.049</ArticleId><ArticleId IdType="pmc">PMC7704606</ArticleId><ArticleId IdType="pubmed">32682869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767&#x2013;783. doi: 10.1016/S1474-4422(20)30221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30221-0</ArticleId><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Loonstra F, Hoitsma E, van Kempen Z, et al. COVID-19 in multiple sclerosis: the Dutch experience. Mult Scler. 2020;26:1256&#x2013;1260. doi: 10.1177/1352458520942198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520942198</ArticleId><ArticleId IdType="pmc">PMC7493197</ArticleId><ArticleId IdType="pubmed">32662742</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallucci G, Zito A, Baldanti F, et al. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. Mult Scler Relat Disord. 2021;49:102754. doi: 10.1016/J.MSARD.2021.102754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102754</ArticleId><ArticleId IdType="pmc">PMC7836789</ArticleId><ArticleId IdType="pubmed">33609958</ArticleId></ArticleIdList></Reference><Reference><Citation>Iovino A, Olivieri N, Aruta F, et al. Alemtuzumab in Covid era. Mult Scler Relat Disord. 2021;51:102908. doi: 10.1016/J.MSARD.2021.102908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102908</ArticleId><ArticleId IdType="pmc">PMC7969858</ArticleId><ArticleId IdType="pubmed">33812222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceronie B, Jacobs BM, Baker D, et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol. 2018;265:1199&#x2013;1209. doi: 10.1007/S00415-018-8830-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-018-8830-Y</ArticleId><ArticleId IdType="pmc">PMC5937883</ArticleId><ArticleId IdType="pubmed">29550884</ArticleId></ArticleIdList></Reference><Reference><Citation>Drulovic J, Ivanovic J, Martinovic V, et al. Humoral response to SARS-CoV-2 and COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies. Mult Scler Relat Disord. 2021;54:103150. doi: 10.1016/J.MSARD.2021.103150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.103150</ArticleId><ArticleId IdType="pmc">PMC8280377</ArticleId><ArticleId IdType="pubmed">34298478</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalla Costa G, Leocani L, Montalban X, et al. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci. 2020;41:1647&#x2013;1650. doi: 10.1007/S10072-020-04519-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10072-020-04519-X</ArticleId><ArticleId IdType="pmc">PMC7331489</ArticleId><ArticleId IdType="pubmed">32617741</ArticleId></ArticleIdList></Reference><Reference><Citation>Woopen C, Schleu&#xdf;ner K, Akg&#xfc;n K, Ziemssen T. Approach to SARS-CoV-2 vaccination in patients with multiple sclerosis. Front Immunol. 2021;12:701752. doi: 10.3389/FIMMU.2021.701752.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.701752</ArticleId><ArticleId IdType="pmc">PMC8256163</ArticleId><ArticleId IdType="pubmed">34234787</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack D, Damian D, Nolting A, Galazka A. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: an update. Mult Scler Relat Disord. 2021;51:102929. doi: 10.1016/J.MSARD.2021.102929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102929</ArticleId><ArticleId IdType="pmc">PMC7997846</ArticleId><ArticleId IdType="pubmed">33813097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabalza A, C&#xe1;rdenas-Robledo S, Tagliani P, et al. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur J Neurol. 2021;28:3384&#x2013;3395. doi: 10.1111/ENE.14690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ENE.14690</ArticleId><ArticleId IdType="pubmed">33340215</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallach A, Picone M. The presence of SARS-CoV2 antibodies in MS patients. Mult Scler Relat Disord. 2021 doi: 10.1016/J.MSARD.2021.102793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102793</ArticleId><ArticleId IdType="pmc">PMC7825833</ArticleId><ArticleId IdType="pubmed">33588315</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili S, Abbasi MH, Abolmaali M, et al. Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD. BMC Neurol. 2021;21:1&#x2013;8. doi: 10.1186/S12883-021-02218-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12883-021-02218-4</ArticleId><ArticleId IdType="pmc">PMC8087518</ArticleId><ArticleId IdType="pubmed">33933026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarahmadi P, Alirezaei M, Forouzannia SM, Naser Moghadasi A. The outcome of COVID-19 in patients with a history of taking rituximab: a narrative review. Iran J Med Sci. 2021;46:411&#x2013;419. doi: 10.30476/IJMS.2021.88717.1946.</Citation><ArticleIdList><ArticleId IdType="doi">10.30476/IJMS.2021.88717.1946</ArticleId><ArticleId IdType="pmc">PMC8611224</ArticleId><ArticleId IdType="pubmed">34840381</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahraian M, Azimi A, Navardi S, et al. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord. 2020;46:102472. doi: 10.1016/J.MSARD.2020.102472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102472</ArticleId><ArticleId IdType="pmc">PMC7456295</ArticleId><ArticleId IdType="pubmed">32890817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardeman P, Mann M, Hughes S, Greenberg B (2016) Does rituximab cause depletion of T-Cells in multiple sclerosis and neuromyelitis optica? (P2.158). Neurology 86</Citation></Reference><Reference><Citation>Maarouf A, Rico A, Boutiere C, et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol Neuroimmunol Neuroinflammation. 2020;7:825. doi: 10.1212/NXI.0000000000000825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000825</ArticleId><ArticleId IdType="pmc">PMC7357416</ArticleId><ArticleId IdType="pubmed">32587103</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazza F, Lapucci C, Cellerino M, et al. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? J Neurol Sci. 2021;427:117501. doi: 10.1016/J.JNS.2021.117501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JNS.2021.117501</ArticleId><ArticleId IdType="pmc">PMC8133824</ArticleId><ArticleId IdType="pubmed">34044238</ArticleId></ArticleIdList></Reference><Reference><Citation>Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195. doi: 10.1016/J.MSARD.2020.102195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102195</ArticleId><ArticleId IdType="pmc">PMC7219389</ArticleId><ArticleId IdType="pubmed">32460086</ArticleId></ArticleIdList></Reference><Reference><Citation>Montero-Escribano P, Mat&#xed;as-Guiu J, G&#xf3;mez-Iglesias P, et al. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185. doi: 10.1016/J.MSARD.2020.102185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102185</ArticleId><ArticleId IdType="pmc">PMC7204643</ArticleId><ArticleId IdType="pubmed">32408147</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer-Gould A, Smith J, Li B. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol. 2021;8:938&#x2013;943. doi: 10.1002/ACN3.51342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ACN3.51342</ArticleId><ArticleId IdType="pmc">PMC8045943</ArticleId><ArticleId IdType="pubmed">33783140</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson-Yap S, De Brouwer E, Kalincik T, et al. First results of the COVID-19 in ms global data sharing initiative suggest anti-CD20 dmts are associated with worse covid-19 outcomes. Web Sci. 2020;26:48&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose G, Galetta K. Reactivation of SARS-CoV-2 after rituximab in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021;52:102922. doi: 10.1016/J.MSARD.2021.102922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102922</ArticleId><ArticleId IdType="pmc">PMC7992302</ArticleId><ArticleId IdType="pubmed">33895693</ArticleId></ArticleIdList></Reference><Reference><Citation>Gousseff M, Penot P, Gallay L, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? J Infect. 2020;81:816&#x2013;846. doi: 10.1016/J.JINF.2020.06.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JINF.2020.06.073</ArticleId><ArticleId IdType="pmc">PMC7326402</ArticleId><ArticleId IdType="pubmed">32619697</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrambide G, Llaneza-Gonz&#xe1;lez M, Costa-Frossard Fran&#xe7;a L, et al. SARS-CoV-2 infection in multiple sclerosis: results of the Spanish Neurology Society Registry. Neurol Neuroimmunol neuroinflammation. 2021;8:e1024. doi: 10.1212/NXI.0000000000001024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001024</ArticleId><ArticleId IdType="pmc">PMC8225011</ArticleId><ArticleId IdType="pubmed">34168057</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Diaz E, Perez-Vicente J, Villaverde-Gonzalez R, et al. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021;8:385&#x2013;394. doi: 10.1002/ACN3.51282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ACN3.51282</ArticleId><ArticleId IdType="pmc">PMC7886031</ArticleId><ArticleId IdType="pubmed">33369288</ArticleId></ArticleIdList></Reference><Reference><Citation>Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77:1079&#x2013;1088. doi: 10.1001/JAMANEUROL.2020.2581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANEUROL.2020.2581</ArticleId><ArticleId IdType="pmc">PMC7320356</ArticleId><ArticleId IdType="pubmed">32589189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes R, Whitley L, Fitovski K, et al. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord. 2021;49:102725. doi: 10.1016/J.MSARD.2020.102725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102725</ArticleId><ArticleId IdType="pmc">PMC7772086</ArticleId><ArticleId IdType="pubmed">33482590</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller T. Antik&#xf6;rper gegen CD 20: ein Risiko in der Pandemie? InFo Neurol Psychiatr. 2020;22:71&#x2013;72. doi: 10.1007/S15005-020-1512-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S15005-020-1512-1</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;hn N, Konen F, Pul R, et al. Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases. J Clin Med. 2020;9:4067. doi: 10.3390/JCM9124067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/JCM9124067</ArticleId><ArticleId IdType="pmc">PMC7766122</ArticleId><ArticleId IdType="pubmed">33339436</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfes L, Pawlitzki M, Pfeuffer S, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol - Neuroimmunol Neuroinflammation. 2021;8:e1035. doi: 10.1212/NXI.0000000000001035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001035</ArticleId><ArticleId IdType="pmc">PMC8362352</ArticleId><ArticleId IdType="pubmed">34261812</ArticleId></ArticleIdList></Reference><Reference><Citation>Barun B, Gabeli&#x107; T, Adamec I, et al. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Mult Scler Relat Disord. 2021;48:102704. doi: 10.1016/J.MSARD.2020.102704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102704</ArticleId><ArticleId IdType="pmc">PMC8021462</ArticleId><ArticleId IdType="pubmed">33370649</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaffaldano P, Lucisano G, Stat M, et al. Risk of getting COVID-19 in people with multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. 2022;9:e1141. doi: 10.1212/NXI.0000000000001141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001141</ArticleId><ArticleId IdType="pmc">PMC8771668</ArticleId><ArticleId IdType="pubmed">35046084</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Yin H, Xu Y, et al. The epidemiology of COVID-19 and MS-related characteristics in a national sample of people with MS in China. Front Neurol. 2021;12:682729. doi: 10.3389/FNEUR.2021.682729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FNEUR.2021.682729</ArticleId><ArticleId IdType="pmc">PMC8193356</ArticleId><ArticleId IdType="pubmed">34122322</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol neuroinflammation. 2021;8:e1001. doi: 10.1212/NXI.0000000000001001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001001</ArticleId><ArticleId IdType="pmc">PMC8142838</ArticleId><ArticleId IdType="pubmed">34016734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dopazo J, Maya-Miles D, Garc&#xed;a F, et al. Implementing personalized medicine in COVID-19 in Andalusia: an opportunity to transform the healthcare system. J Pers Med. 2021;11:475. doi: 10.3390/JPM11060475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/JPM11060475</ArticleId><ArticleId IdType="pmc">PMC8226500</ArticleId><ArticleId IdType="pubmed">34073493</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzegar M, Vaheb S, Mirmosayyeb O, et al. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study. Mult Scler Relat Disord. 2021;52:102947. doi: 10.1016/J.MSARD.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8036166</ArticleId><ArticleId IdType="pubmed">33979771</ArticleId></ArticleIdList></Reference><Reference><Citation>Boziki M, Mentis A, Shumilina M, et al. COVID-19 immunopathology and the central nervous system: implication for multiple sclerosis and other autoimmune diseases with associated demyelination. Brain Sci. 2020;10:345. doi: 10.3390/BRAINSCI10060345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/BRAINSCI10060345</ArticleId><ArticleId IdType="pmc">PMC7349282</ArticleId><ArticleId IdType="pubmed">32512702</ArticleId></ArticleIdList></Reference><Reference><Citation>Buljevac D, Flach H, Hop W, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125:952&#x2013;960. doi: 10.1093/BRAIN/AWF098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/BRAIN/AWF098</ArticleId><ArticleId IdType="pubmed">11960885</ArticleId></ArticleIdList></Reference><Reference><Citation>Paules C, Marston H, Fauci A. Coronavirus infections-more than just the common cold. JAMA. 2020;323:707&#x2013;708. doi: 10.1001/JAMA.2020.0757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.0757</ArticleId><ArticleId IdType="pubmed">31971553</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27:1451&#x2013;1454. doi: 10.1038/s41418-020-0530-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-0530-3</ArticleId><ArticleId IdType="pmc">PMC7091918</ArticleId><ArticleId IdType="pubmed">32205856</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, Romani L, Bernitsas E. Could Sars-Cov2 affect MS progression? Mult Scler Relat Disord. 2020 doi: 10.1016/j.msard.2020.102540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102540</ArticleId><ArticleId IdType="pmc">PMC7524432</ArticleId><ArticleId IdType="pubmed">33032060</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355&#x2013;362. doi: 10.1038/s41577-020-0331-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziedzic A, Saluk-bijak J, Miller E, et al. The impact of sars-cov-2 infection on the development of neurodegeneration in multiple sclerosis. Int J Mol Sci. 2021;22:1&#x2013;23. doi: 10.3390/ijms22041804.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041804</ArticleId><ArticleId IdType="pmc">PMC7918534</ArticleId><ArticleId IdType="pubmed">33670394</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52:910&#x2013;941. doi: 10.1016/J.IMMUNI.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IMMUNI.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Garjani A, Middleton R, Hunter R, et al. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Mult Scler Relat Disord. 2021;52:102939. doi: 10.1016/J.MSARD.2021.102939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102939</ArticleId><ArticleId IdType="pmc">PMC9585399</ArticleId><ArticleId IdType="pubmed">34010764</ArticleId></ArticleIdList></Reference><Reference><Citation>Etemadifar M, Sedaghat N, Aghababaee A, et al. COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect? Mult Scler Relat Disord. 2021;51:102915. doi: 10.1016/J.MSARD.2021.102915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102915</ArticleId><ArticleId IdType="pmc">PMC7980521</ArticleId><ArticleId IdType="pubmed">33799284</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker D, Amor S, Kang AS, et al. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020;43:102174. doi: 10.1016/J.MSARD.2020.102174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102174</ArticleId><ArticleId IdType="pmc">PMC7214323</ArticleId><ArticleId IdType="pubmed">32464584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulikowska J, Kulczy&#x144;ska-Przybik A, Mroczko B, Ku&#x142;akowska A. The significance of COVID-19 immunological status in severe neurological complications and multiple sclerosis&#x2014;a literature review. Int J Mol Sci. 2021;22:5894. doi: 10.3390/IJMS22115894.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IJMS22115894</ArticleId><ArticleId IdType="pmc">PMC8199258</ArticleId><ArticleId IdType="pubmed">34072715</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancho-Salda&#xf1;a A, S&#xe1;nchez AG, Quirant-S&#xe1;nchez B, et al. Seroprevalence of SARS-CoV-2 in a cohort of patients with multiple sclerosis under disease-modifying therapies. J Clin Med. 2022;11:2509. doi: 10.3390/JCM11092509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/JCM11092509</ArticleId><ArticleId IdType="pmc">PMC9099725</ArticleId><ArticleId IdType="pubmed">35566632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigaut K, Kremer L, Fabacher T, et al. Impact of disease-modifying treatments of multiple sclerosis on anti-SARS-CoV-2 antibodies: an observational study. Neurol Neuroimmunol Neuroinflammation. 2021 doi: 10.1212/NXI.0000000000001055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001055</ArticleId><ArticleId IdType="pmc">PMC8362343</ArticleId><ArticleId IdType="pubmed">34321333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bsteh G, D&#xfc;rauer S, Assar H, et al. Humoral immune response after COVID-19 in multiple sclerosis: a nation-wide Austrian study. Mult Scler. 2021;27:2209&#x2013;2218. doi: 10.1177/13524585211049391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585211049391</ArticleId><ArticleId IdType="pmc">PMC8597187</ArticleId><ArticleId IdType="pubmed">34595968</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte W. Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: a case-control study. Mult Scler Relat Disord. 2021;52:103014. doi: 10.1016/J.MSARD.2021.103014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.103014</ArticleId><ArticleId IdType="pmc">PMC8102087</ArticleId><ArticleId IdType="pubmed">34000684</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte WL. Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia. Mult Scler Relat Disord. 2020;44:102315. doi: 10.1016/J.MSARD.2020.102315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102315</ArticleId><ArticleId IdType="pmc">PMC7305883</ArticleId><ArticleId IdType="pubmed">32593144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchini M, Bianco A, Del GP, et al. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report. Mult Scler Relat Disord. 2020;44:102323. doi: 10.1016/J.MSARD.2020.102323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102323</ArticleId><ArticleId IdType="pmc">PMC7307994</ArticleId><ArticleId IdType="pubmed">32593961</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton JR, Harel A. Negative SARS-CoV-2 antibody testing following COVID-19 infection in two MS patients treated with ocrelizumab. Mult Scler Relat Disord. 2020;44:102341. doi: 10.1016/J.MSARD.2020.102341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2020.102341</ArticleId><ArticleId IdType="pmc">PMC7318946</ArticleId><ArticleId IdType="pubmed">32622338</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannetta M, Landi D, Cola G, et al. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. Mult Scler Relat Disord. 2021;55:103157. doi: 10.1016/J.MSARD.2021.103157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.103157</ArticleId><ArticleId IdType="pmc">PMC8291995</ArticleId><ArticleId IdType="pubmed">34418737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183:158&#x2013;168.e14. doi: 10.1016/J.CELL.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelibter S, Orrico M, Filippi M, Moiola L. COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: implication for vaccination program? Mult Scler Relat Disord. 2021;49:102775. doi: 10.1016/J.MSARD.2021.102775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102775</ArticleId><ArticleId IdType="pmc">PMC7817400</ArticleId><ArticleId IdType="pubmed">33517176</ArticleId></ArticleIdList></Reference><Reference><Citation>Habek M, Jakob Brecl G, Ba&#x161;i&#x107; Kes V, et al. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: a multicenter, case-control study. J Neuroimmunol. 2021;359:577696. doi: 10.1016/J.JNEUROIM.2021.577696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JNEUROIM.2021.577696</ArticleId><ArticleId IdType="pmc">PMC8366037</ArticleId><ArticleId IdType="pubmed">34418815</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Gonzalez RE, Hernandez J, Tornes L, et al. Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab. Mult Scler Relat Disord. 2021;49:102777. doi: 10.1016/J.MSARD.2021.102777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102777</ArticleId><ArticleId IdType="pmc">PMC7816891</ArticleId><ArticleId IdType="pubmed">33508573</ArticleId></ArticleIdList></Reference><Reference><Citation>Galleguillos L, Alonso R. Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis. Mult Scler Relat Disord. 2021;54:103142. doi: 10.1016/J.MSARD.2021.103142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.103142</ArticleId><ArticleId IdType="pmc">PMC8284074</ArticleId><ArticleId IdType="pubmed">34298479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol. 2021;356:577599. doi: 10.1016/J.JNEUROIM.2021.577599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JNEUROIM.2021.577599</ArticleId><ArticleId IdType="pmc">PMC8095041</ArticleId><ArticleId IdType="pubmed">34000472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354. doi: 10.3389/FIMMU.2020.585354.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2020.585354</ArticleId><ArticleId IdType="pmc">PMC7591699</ArticleId><ArticleId IdType="pubmed">33163000</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https://covid19.who.int/?gclid=Cj0KCQiA6t6ABhDMARIsAONIYywpPDg3HucQtbypR3MmCf9RzstxhVodEx73VZCfpbDuLfpNoy-73caAvp_EALw_wcB. Accessed 26 May 2022</Citation></Reference><Reference><Citation>Buttari F, Bruno A, Dolcetti E, et al. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Mult Scler Relat Disord. 2021;52:102983. doi: 10.1016/J.MSARD.2021.102983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102983</ArticleId><ArticleId IdType="pmc">PMC8093161</ArticleId><ArticleId IdType="pubmed">33990054</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniscalco GT, Manzo V, Di BME, et al. Severe multiple sclerosis relapse after COVID-19 vaccination: a case report. Front Neurol. 2021;12:721502. doi: 10.3389/FNEUR.2021.721502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FNEUR.2021.721502</ArticleId><ArticleId IdType="pmc">PMC8382847</ArticleId><ArticleId IdType="pubmed">34447349</ArticleId></ArticleIdList></Reference><Reference><Citation>Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler. 2021;27:864&#x2013;870. doi: 10.1177/13524585211003476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585211003476</ArticleId><ArticleId IdType="pmc">PMC8114441</ArticleId><ArticleId IdType="pubmed">33856242</ArticleId></ArticleIdList></Reference><Reference><Citation>Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021 doi: 10.1177/17562864211012835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562864211012835</ArticleId><ArticleId IdType="pmc">PMC8072850</ArticleId><ArticleId IdType="pubmed">34035836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariottini A, Bertozzi A, Marchi L, et al. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. J Neurol. 2022;269:2840&#x2013;2847. doi: 10.1007/S00415-022-11003-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-022-11003-3</ArticleId><ArticleId IdType="pmc">PMC8891428</ArticleId><ArticleId IdType="pubmed">35239006</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G, Sacco R, Bernasconi E, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol. 2021;78:1529&#x2013;1531. doi: 10.1001/JAMANEUROL.2021.3609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANEUROL.2021.3609</ArticleId><ArticleId IdType="pmc">PMC8461551</ArticleId><ArticleId IdType="pubmed">34554185</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakimovski D, Zakalik K, Awan S, et al. COVID-19 vaccination in multiple sclerosis and inflammatory diseases: effects from disease-modifying therapy, long-term seroprevalence and breakthrough infections. Vaccines. 2022;10:695. doi: 10.3390/VACCINES10050695.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/VACCINES10050695</ArticleId><ArticleId IdType="pmc">PMC9146267</ArticleId><ArticleId IdType="pubmed">35632451</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nig M, Torgauten HM, Tran TT, et al. Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination. JAMA Neurol. 2022;79:307&#x2013;309. doi: 10.1001/JAMANEUROL.2021.5109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANEUROL.2021.5109</ArticleId><ArticleId IdType="pmc">PMC8787678</ArticleId><ArticleId IdType="pubmed">35072702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ag&#xfc;era E (2021) Vacuna Covid en pacientes con EM. Evidencias disponibles. In: Jornadas de actualizaci&#xf3;n: Novedades en Prevenci&#xf3;n, Manejo de infecciones y vacunas en Esclerosis M&#xfa;ltiple</Citation></Reference><Reference><Citation>Ciotti JR, Perantie DC, Moss BP, et al. Perspectives and experiences with COVID-19 vaccines in people with MS. Mult Scler J Exp Transl Clin. 2022 doi: 10.1177/20552173221085242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20552173221085242</ArticleId><ArticleId IdType="pmc">PMC8902317</ArticleId><ArticleId IdType="pubmed">35273809</ArticleId></ArticleIdList></Reference><Reference><Citation>Capone F, Lucchini M, Ferraro E, et al. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics. 2021;19:325&#x2013;333. doi: 10.1007/S13311-021-01165-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S13311-021-01165-9</ArticleId><ArticleId IdType="pmc">PMC8639214</ArticleId><ArticleId IdType="pubmed">34859382</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs FBS, Mateen FJ, Schmidt H, et al. COVID-19 vaccination reactogenicity in persons with multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. 2022 doi: 10.1212/NXI.0000000000001104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001104</ArticleId><ArticleId IdType="pmc">PMC8579248</ArticleId><ArticleId IdType="pubmed">34753828</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero-Romero S, Ascherio A, Lebrun-Fr&#xe9;nay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol. 2021;34:322&#x2013;328. doi: 10.1097/WCO.0000000000000929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000929</ArticleId><ArticleId IdType="pubmed">33709979</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Multiple Sclerosis Society COVID-19 Vaccine Guidance for People Living with MS. https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-Vaccines. Accessed 14 Oct 2021</Citation></Reference><Reference><Citation>Korsukewitz C, Reddel S, Bar-Or A, Wiendl H. Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature. Nat Rev Neurol. 2020;16:493&#x2013;505. doi: 10.1038/S41582-020-0385-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41582-020-0385-8</ArticleId><ArticleId IdType="pmc">PMC7341707</ArticleId><ArticleId IdType="pubmed">32641860</ArticleId></ArticleIdList></Reference><Reference><Citation>Costagliola G, Spada E, Comberiati P, Peroni D. Could nutritional supplements act as therapeutic adjuvants in COVID-19? Ital J Pediatr. 2021;47:32. doi: 10.1186/S13052-021-00990-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13052-021-00990-0</ArticleId><ArticleId IdType="pmc">PMC7883952</ArticleId><ArticleId IdType="pubmed">33588905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9:599&#x2013;612. doi: 10.1016/S1474-4422(10)70086-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70086-7</ArticleId><ArticleId IdType="pubmed">20494325</ArticleId></ArticleIdList></Reference><Reference><Citation>Golan D, Staun-Ram E, Glass-Marmor L, et al. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun. 2013;32:180&#x2013;185. doi: 10.1016/j.bbi.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2013.04.010</ArticleId><ArticleId IdType="pubmed">23665342</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant W, Lahore H, McDonnell S, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12:988. doi: 10.3390/NU12040988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/NU12040988</ArticleId><ArticleId IdType="pmc">PMC7352449</ArticleId><ArticleId IdType="pubmed">32492787</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocayar-Mar&#xf3;n FJ, Ferder L, Reiter RJ, Manucha W. Daily and seasonal mitochondrial protection: unraveling common possible mechanisms involving vitamin D and melatonin. J Steroid Biochem Mol Biol. 2020;199:105595. doi: 10.1016/j.jsbmb.2020.105595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2020.105595</ArticleId><ArticleId IdType="pubmed">31954766</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdollahzadeh R, Shushizadeh M, Barazandehrokh M, et al. Association of Vitamin D receptor gene polymorphisms and clinical/severe outcomes of COVID-19 patients. Infect Genet Evol. 2021;96:105098. doi: 10.1016/J.MEEGID.2021.105098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MEEGID.2021.105098</ArticleId><ArticleId IdType="pmc">PMC8487094</ArticleId><ArticleId IdType="pubmed">34610433</ArticleId></ArticleIdList></Reference><Reference><Citation>Dankers W, Colin E, van Hamburg J, Lubberts E. Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential. Front Immunol. 2017;7:697. doi: 10.3389/FIMMU.2016.00697.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2016.00697</ArticleId><ArticleId IdType="pmc">PMC5247472</ArticleId><ArticleId IdType="pubmed">28163705</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salem K, Khalil H, Al-Sharman A, et al. Serum vitamin d inversely correlates with depression scores in people with multiple sclerosis. Mult Scler Relat Disord. 2021 doi: 10.1016/j.msard.2020.102732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2020.102732</ArticleId><ArticleId IdType="pubmed">33422916</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale J, Ysrraelit M, Gait&#xe1;n M. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009;132:1146&#x2013;1160. doi: 10.1093/BRAIN/AWP033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/BRAIN/AWP033</ArticleId><ArticleId IdType="pubmed">19321461</ArticleId></ArticleIdList></Reference><Reference><Citation>Soilu-H&#xe4;nninen M, Laaksonen M, Laitinen I, et al. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79:152&#x2013;157. doi: 10.1136/JNNP.2006.105320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/JNNP.2006.105320</ArticleId><ArticleId IdType="pubmed">17578859</ArticleId></ArticleIdList></Reference><Reference><Citation>Soilu-H&#xe4;nninen M, Airas L, Mononen I, et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler. 2005;11:266&#x2013;271. doi: 10.1191/1352458505MS1157OA.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1352458505MS1157OA</ArticleId><ArticleId IdType="pubmed">15957505</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayawardena R, Sooriyaarachchi P, Chourdakis M, et al. Enhancing immunity in viral infections, with special emphasis on COVID-19: a review. Diabetes Metab Syndr. 2020;14:367&#x2013;382. doi: 10.1016/J.DSX.2020.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.DSX.2020.04.015</ArticleId><ArticleId IdType="pmc">PMC7161532</ArticleId><ArticleId IdType="pubmed">32334392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakaloudi D, Chourdakis M. A critical update on the role of mild and serious vitamin D deficiency prevalence and the COVID-19 epidemic in Europe. Nutrition. 2021;93:111441. doi: 10.1016/J.NUT.2021.111441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NUT.2021.111441</ArticleId><ArticleId IdType="pmc">PMC8321689</ArticleId><ArticleId IdType="pubmed">34492624</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustina A. Hypovitaminosis D and the endocrine phenotype of COVID-19. Endocrine. 2021;72:1&#x2013;11. doi: 10.1007/S12020-021-02671-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12020-021-02671-8</ArticleId><ArticleId IdType="pmc">PMC7972333</ArticleId><ArticleId IdType="pubmed">33738708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari D, Locatelli M, Briguglio M, Lombardi G. Is there a link between vitamin D status, SARS-CoV-2 infection risk and COVID-19 severity? Cell Biochem Funct. 2021;39:35&#x2013;47. doi: 10.1002/CBF.3597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/CBF.3597</ArticleId><ArticleId IdType="pubmed">33137851</ArticleId></ArticleIdList></Reference><Reference><Citation>Benskin L. A basic review of the preliminary evidence that COVID-19 risk and severity is increased in Vitamin D deficiency. Front public Heal. 2020;8:513. doi: 10.3389/FPUBH.2020.00513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FPUBH.2020.00513</ArticleId><ArticleId IdType="pmc">PMC7513835</ArticleId><ArticleId IdType="pubmed">33014983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemb P, Bergman P, Camargo CA, et al. Vitamin D deficiency and the COVID-19 pandemic. J Glob Antimicrob Resist. 2020;22:133. doi: 10.1016/J.JGAR.2020.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JGAR.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7256612</ArticleId><ArticleId IdType="pubmed">32474141</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529. doi: 10.1007/S00281-017-0629-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00281-017-0629-X</ArticleId><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin&#x2013;angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41:1801&#x2013;1803. doi: 10.1093/EURHEARTJ/EHAA235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/EURHEARTJ/EHAA235</ArticleId><ArticleId IdType="pmc">PMC7184407</ArticleId><ArticleId IdType="pubmed">32196087</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Qiao G, Uskokovic M, et al. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89&#x2013;90:387&#x2013;392. doi: 10.1016/J.JSBMB.2004.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JSBMB.2004.03.004</ArticleId><ArticleId IdType="pubmed">15225806</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc. 2012;71:50&#x2013;61. doi: 10.1017/S0029665111001650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665111001650</ArticleId><ArticleId IdType="pubmed">21849106</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassi F, Tamone C, D&#x2019;Amelio P. Vitamin D: nutrient, hormone, and immunomodulator. Nutrients. 2018;10:1656. doi: 10.3390/NU10111656.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/NU10111656</ArticleId><ArticleId IdType="pmc">PMC6266123</ArticleId><ArticleId IdType="pubmed">30400332</ArticleId></ArticleIdList></Reference><Reference><Citation>Gois P, Ferreira D, Olenski S, Seguro A. Vitamin D and infectious diseases: simple bystander or contributing factor? Nutrients. 2017;9:651. doi: 10.3390/NU9070651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/NU9070651</ArticleId><ArticleId IdType="pmc">PMC5537771</ArticleId><ArticleId IdType="pubmed">28672783</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasheghani M, Jannati N, Baghaei P, et al. The relationship between serum 25-hydroxyvitamin D levels and the severity of COVID-19 disease and its mortality. Sci Rep. 2021;11:1&#x2013;11. doi: 10.1038/s41598-021-97017-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-97017-9</ArticleId><ArticleId IdType="pmc">PMC8413335</ArticleId><ArticleId IdType="pubmed">34475485</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamir Y, Amir H, Lim S, et al. A randomized pilot study using calcitriol in hospitalized COVID-19 patients. Bone. 2021;154:116175. doi: 10.1016/J.BONE.2021.116175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BONE.2021.116175</ArticleId><ArticleId IdType="pmc">PMC8425676</ArticleId><ArticleId IdType="pubmed">34508882</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo ME, Costa LME, Barrios JMV, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203:105751. doi: 10.1016/J.JSBMB.2020.105751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JSBMB.2020.105751</ArticleId><ArticleId IdType="pmc">PMC7456194</ArticleId><ArticleId IdType="pubmed">32871238</ArticleId></ArticleIdList></Reference><Reference><Citation>Loucera C, Pe&#xf1;a-Chilet M, Esteban-Medina M, et al. Real world evidence of calcifediol use and mortality rate of COVID-19 hospitalized in a large cohort of 16,401 Andalusian patients. medRxiv. 2021;11:23380. doi: 10.1101/2021.04.27.21255937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.27.21255937</ArticleId><ArticleId IdType="pmc">PMC8642445</ArticleId><ArticleId IdType="pubmed">34862422</ArticleId></ArticleIdList></Reference><Reference><Citation>Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. 2021;325:1053&#x2013;1060. doi: 10.1001/JAMA.2020.26848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.26848</ArticleId><ArticleId IdType="pmc">PMC7890452</ArticleId><ArticleId IdType="pubmed">33595634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman P. The link between vitamin D and COVID-19: distinguishing facts from fiction. J Intern Med. 2021;289:131&#x2013;133. doi: 10.1111/JOIM.13158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JOIM.13158</ArticleId><ArticleId IdType="pmc">PMC7405052</ArticleId><ArticleId IdType="pubmed">32652766</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Pioggia G, Negrini S. Vitamin D and Covid-19: an update on evidence and potential therapeutic implications. Clin Mol Allergy. 2020;18:23. doi: 10.1186/S12948-020-00139-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12948-020-00139-0</ArticleId><ArticleId IdType="pmc">PMC7675394</ArticleId><ArticleId IdType="pubmed">33292313</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda E, Bogliolo L, Lobascio F, et al. Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy. Nutrition. 2021;82:111055. doi: 10.1016/J.NUT.2020.111055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NUT.2020.111055</ArticleId><ArticleId IdType="pmc">PMC7657015</ArticleId><ArticleId IdType="pubmed">33288411</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Diabetes &amp; Endocrinology Vitamin D and COVID-19: why the controversy? Lancet Diabetes Endocrinol. 2021;9:53. doi: 10.1016/S2213-8587(21)00003-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00003-6</ArticleId><ArticleId IdType="pmc">PMC9765136</ArticleId><ArticleId IdType="pubmed">33444566</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrascal L, Nunez-Abades P, Ayala A, Cano M. Role of melatonin in the inflammatory process and its therapeutic potential. Curr Pharm Des. 2018;24:1563&#x2013;1588. doi: 10.2174/1381612824666180426112832.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612824666180426112832</ArticleId><ArticleId IdType="pubmed">29701146</ArticleId></ArticleIdList></Reference><Reference><Citation>Escribano BM, Colin-Gonzalez A, Santamaria A, Tunez I. The role of melatonin in multiple sclerosis, huntington&#x2019;s disease and cerebral ischemia. CNS Neurol Disord Drug Targets. 2014;13:1096&#x2013;1119. doi: 10.2174/1871527313666140806160400.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527313666140806160400</ArticleId><ArticleId IdType="pubmed">25106623</ArticleId></ArticleIdList></Reference><Reference><Citation>Onaolapo OJ, Onaolapo AY, Olowe OA, et al. Melatonin and melatonergic influence on neuronal transcription factors: implications for the development of novel therapies for neurodegenerative disorders. Curr Neuropharmacol. 2019;18:563&#x2013;577. doi: 10.2174/1570159x18666191230114339.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159x18666191230114339</ArticleId><ArticleId IdType="pmc">PMC7457420</ArticleId><ArticleId IdType="pubmed">31885352</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern S, Geiger M, Paucke M, et al. Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis. J Mol Med. 2019;97:1547&#x2013;1555. doi: 10.1007/s00109-019-01821-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-019-01821-w</ArticleId><ArticleId IdType="pubmed">31471628</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;lvarez-S&#xe1;nchez N, Cruz-Chamorro I, D&#xed;az-S&#xe1;nchez M, et al. Melatonin reduces inflammatory response in peripheral T helper lymphocytes from relapsing-remitting multiple sclerosis patients. J Pineal Res. 2017 doi: 10.1111/jpi.12442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12442</ArticleId><ArticleId IdType="pubmed">28793364</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitimus DM, Popescu MR, Voiculescu SE, et al. Melatonin&#x2019;s impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease. Biomolecules. 2020;10:1&#x2013;28. doi: 10.3390/biom10091211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10091211</ArticleId><ArticleId IdType="pmc">PMC7563541</ArticleId><ArticleId IdType="pubmed">32825327</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;lvarez-S&#xe1;nchez N, Cruz-Chamorro I, L&#xf3;pez-Gonz&#xe1;lez A, et al. Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance. Brain Behav Immun. 2015;50:101&#x2013;114. doi: 10.1016/j.bbi.2015.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.06.021</ArticleId><ArticleId IdType="pubmed">26130320</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G, Rodriguez M, Reiter RJ. Multiple sclerosis: Melatonin, orexin, and ceramide interact with platelet activation coagulation factors and gut-microbiome-derived butyrate in the circadian dysregulation of mitochondria in glia and immune cells. Int J Mol Sci. 2019;20:5500. doi: 10.3390/ijms20215500.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20215500</ArticleId><ArticleId IdType="pmc">PMC6862663</ArticleId><ArticleId IdType="pubmed">31694154</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-L&#xf3;pez AL, Ortiz GG, Pacheco-Moises FP, et al. Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis. Arch Med Res. 2018;49:391&#x2013;398. doi: 10.1016/j.arcmed.2018.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2018.12.004</ArticleId><ArticleId IdType="pubmed">30595364</ArticleId></ArticleIdList></Reference><Reference><Citation>Yosefifard M, Vaezi G, Malekirad AA, et al. A randomized control trial study to determine the effect of melatonin on serum levels of IL-1&#x3b2; and TNF-&#x3b1; in patients with multiple sclerosis. Iran J Allergy Asthma Immunol. 2019;18:649&#x2013;654. doi: 10.18502/ijaai.v18i6.2177.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijaai.v18i6.2177</ArticleId><ArticleId IdType="pubmed">32245308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima S, Zaidi SS, Alsharidah AS, et al. Possible prophylactic approach for SARS-CoV-2 infection by combination of melatonin, vitamin C and zinc in animals. Front Vet Sci. 2020 doi: 10.3389/fvets.2020.585789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fvets.2020.585789</ArticleId><ArticleId IdType="pmc">PMC7744567</ArticleId><ArticleId IdType="pubmed">33344529</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter RJ, Tan DX, Galano A. Melatonin reduces lipid peroxidation and membrane viscosity. Front Physiol. 2014;5:377. doi: 10.3389/fphys.2014.00377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2014.00377</ArticleId><ArticleId IdType="pmc">PMC4186275</ArticleId><ArticleId IdType="pubmed">25339906</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfa;nez I, Montilla P, Mu&#xf1;oz MDC, et al. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington&#x2019;s disease. J Pineal Res. 2004;37:252&#x2013;256. doi: 10.1111/j.1600-079X.2004.00163.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00163.x</ArticleId><ArticleId IdType="pubmed">15485551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahamonde C, Conde C, Ag&#xfc;era E, et al. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress. Eur J Pharmacol. 2014;730:26&#x2013;30. doi: 10.1016/j.ejphar.2014.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2014.02.020</ArticleId><ArticleId IdType="pubmed">24582759</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto-Brambila AP, Gabriel Ortiz G, Rivero-Moragrega P, et al. Relapsing remitting multiple sclerosis and its relationship with the immune system and oxidative stress. Curr Immunol Rev. 2017;14:15&#x2013;23. doi: 10.2174/1573395514666171226154300.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573395514666171226154300</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamczyk-Sowa M, Galiniak S, Zyracka E, et al. Oxidative modification of blood serum proteins in multiple sclerosis after interferon beta and melatonin treatment. Oxid Med Cell Longev. 2017 doi: 10.1155/2017/7905148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7905148</ArticleId><ArticleId IdType="pmc">PMC5664347</ArticleId><ArticleId IdType="pubmed">29181127</ArticleId></ArticleIdList></Reference><Reference><Citation>AboTaleb HA, Alghamdi BS. Neuroprotective effects of melatonin during demyelination and remyelination stages in a mouse model of multiple sclerosis. J Mol Neurosci. 2020;70:386&#x2013;402. doi: 10.1007/s12031-019-01425-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-019-01425-6</ArticleId><ArticleId IdType="pubmed">31713152</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi BS, AboTaleb HA. Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex. J Integr Neurosci. 2020;19:229&#x2013;237. doi: 10.31083/j.jin.2020.02.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.jin.2020.02.32</ArticleId><ArticleId IdType="pubmed">32706187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wongchitrat P, Shukla M, Sharma R, et al. Role of melatonin on virus-induced neuropathogenesis&#x2014;a concomitant therapeutic strategy to understand SARS-CoV-2 infection. Antioxidants. 2021;10:1&#x2013;31. doi: 10.3390/antiox10010047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10010047</ArticleId><ArticleId IdType="pmc">PMC7823793</ArticleId><ArticleId IdType="pubmed">33401749</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespo I, San-Miguel B, S&#xe1;nchez DI, et al. Melatonin inhibits the sphingosine kinase 1/sphingosine-1-phosphate signaling pathway in rabbits with fulminant hepatitis of viral origin. J Pineal Res. 2016;61:168&#x2013;176. doi: 10.1111/jpi.12335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12335</ArticleId><ArticleId IdType="pubmed">27101794</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SH, Liao CL, Chen SJ, et al. Melatonin possesses an anti-influenza potential through its immune modulatory effect. J Funct Foods. 2019;58:189&#x2013;198. doi: 10.1016/j.jff.2019.04.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jff.2019.04.062</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero A, Ramos E, L&#xf3;pez-Mu&#xf1;oz F, et al. Coronavirus disease 2019 (COVID-19) and its neuroinvasive capacity: is it time for melatonin? Cell Mol Neurobiol. 2020;42:489&#x2013;500. doi: 10.1007/s10571-020-00938-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00938-8</ArticleId><ArticleId IdType="pmc">PMC7415199</ArticleId><ArticleId IdType="pubmed">32772307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C, Yoo K, Choi J, et al. Melatonin&#x2019;s protective action against ischemic neuronal damage is associated with up-regulation of the MT2 melatonin receptor. J Neurosci Res. 2010;88:2630&#x2013;2640. doi: 10.1002/JNR.22430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JNR.22430</ArticleId><ArticleId IdType="pubmed">20544829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Wang X, Ni L, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. doi: 10.1016/j.lfs.2020.117583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117583</ArticleId><ArticleId IdType="pmc">PMC7102583</ArticleId><ArticleId IdType="pubmed">32217117</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi S, Nabavi S, Sureda A, et al. Anti-inflammatory effects of melatonin: a mechanistic review. Crit Rev Food Sci Nutr. 2019;59:S4&#x2013;S16. doi: 10.1080/10408398.2018.1487927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2018.1487927</ArticleId><ArticleId IdType="pubmed">29902071</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamczyk-Sowa M, Mado H, Kubicka-B&#x105;czyk K, et al. SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy. Clin Neurol Neurosurg. 2021;201:106451. doi: 10.1016/J.CLINEURO.2020.106451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CLINEURO.2020.106451</ArticleId><ArticleId IdType="pmc">PMC7831713</ArticleId><ArticleId IdType="pubmed">33388661</ArticleId></ArticleIdList></Reference><Reference><Citation>Heming M, Li X, R&#xe4;uber S, et al. Neurological manifestations of COVID-19 feature T cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid. Immunity. 2021;54:164&#x2013;175.e6. doi: 10.1016/J.IMMUNI.2020.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IMMUNI.2020.12.011</ArticleId><ArticleId IdType="pmc">PMC7831653</ArticleId><ArticleId IdType="pubmed">33382973</ArticleId></ArticleIdList></Reference><Reference><Citation>Losy J. SARS-CoV-2 infection: symptoms of the nervous system and implications for therapy in neurological disorders. Neurol Ther. 2021;10:31&#x2013;42. doi: 10.1007/S40120-020-00225-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S40120-020-00225-0</ArticleId><ArticleId IdType="pmc">PMC7681771</ArticleId><ArticleId IdType="pubmed">33226565</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliviero A, de Castro F, Coperchini F, et al. COVID-19 pulmonary and olfactory dysfunctions: is the chemokine CXCL10 the common denominator? Neurosci. 2021;27:214&#x2013;221. doi: 10.1177/1073858420939033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858420939033</ArticleId><ArticleId IdType="pubmed">32659199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien J, Chiesa-Estomba C, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288:335&#x2013;344. doi: 10.1111/JOIM.13089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JOIM.13089</ArticleId><ArticleId IdType="pmc">PMC7267446</ArticleId><ArticleId IdType="pubmed">32352202</ArticleId></ArticleIdList></Reference><Reference><Citation>Luers J, Rokohl A, Loreck N, et al. Olfactory and gustatory dysfunction in coronavirus disease 2019 (COVID-19) Clin Infect Dis. 2020;71:2262&#x2013;2264. doi: 10.1093/CID/CIAA525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAA525</ArticleId><ArticleId IdType="pmc">PMC7197599</ArticleId><ArticleId IdType="pubmed">32357210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheraton M, Deo N, Kashyap R, Surani S. A review of neurological complications of COVID-19. Cureus. 2020;12:e8192. doi: 10.7759/CUREUS.8192.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/CUREUS.8192</ArticleId><ArticleId IdType="pmc">PMC7243063</ArticleId><ArticleId IdType="pubmed">32455089</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair AS, McAlpine LS, Gardin T, et al. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77:1018&#x2013;1027. doi: 10.1001/JAMANEUROL.2020.2065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANEUROL.2020.2065</ArticleId><ArticleId IdType="pmc">PMC7484225</ArticleId><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos H, Magira E, Bitzogli K, et al. Anti&#x2013;SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome. Neurol Neuroimmunol Neuroinflammation. 2020;7:893. doi: 10.1212/NXI.0000000000000893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000893</ArticleId><ArticleId IdType="pmc">PMC7577546</ArticleId><ArticleId IdType="pubmed">32978291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataria S, Tandon M, Melnic V, Sriwastava S. A case series and literature review of multiple sclerosis and COVID-19: clinical characteristics, outcomes and a brief review of immunotherapies. Eneurologicalsci. 2020 doi: 10.1016/j.ensci.2020.100287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2020.100287</ArticleId><ArticleId IdType="pmc">PMC7605741</ArticleId><ArticleId IdType="pubmed">33163634</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalaby NM, Shehata HS. Could SARS-CoV-2 herald a surge of multiple sclerosis? Egypt J Neurol Psychiatry Neurosurg. 2021;57:22. doi: 10.1186/S41983-021-00277-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S41983-021-00277-5</ArticleId><ArticleId IdType="pmc">PMC7874024</ArticleId><ArticleId IdType="pubmed">33584093</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot PJ, Boucher A, Duquette P, Gruslin E (2005) Coronaviruses and Neuroantigens: myelin proteins, myelin genes. In: Experimental Models of Multiple Sclerosis. Nature Publishing Group, pp 781&#x2013;791</Citation></Reference><Reference><Citation>Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013;13:3&#x2013;9. doi: 10.1586/14737175.2013.865866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.2013.865866</ArticleId><ArticleId IdType="pubmed">24289836</ArticleId></ArticleIdList></Reference><Reference><Citation>Long T, Yang Y, Peng L, Li Z. Neuroprotective effects of melatonin on experimental allergic encephalomyelitis mice via anti-oxidative stress activity. J Mol Neurosci. 2018;64:233&#x2013;241. doi: 10.1007/s12031-017-1022-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-017-1022-x</ArticleId><ArticleId IdType="pubmed">29450696</ArticleId></ArticleIdList></Reference><Reference><Citation>Mat&#xed;as-Guiu J, Gomez-Pinedo U, Montero-Escribano P, et al. Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurologia. 2020;35:170&#x2013;175. doi: 10.1016/j.nrl.2020.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrl.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7136883</ArticleId><ArticleId IdType="pubmed">32299636</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray R, Brown B, Brian D, Cabirac G. Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann Neurol. 1992;31:525&#x2013;533. doi: 10.1002/ANA.410310511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ANA.410310511</ArticleId><ArticleId IdType="pmc">PMC7159714</ArticleId><ArticleId IdType="pubmed">1596089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristallo A, G&#xe1;mbaro F, Biamonti G, et al. Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. New Microbiol. 1997;20:105&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9208420</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoso YD, Pacheco FAS, Silveira GL, et al. COVID-19 in a temporal relation to the onset of multiple sclerosis. Mult Scler Relat Disord. 2021;50:102863. doi: 10.1016/J.MSARD.2021.102863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MSARD.2021.102863</ArticleId><ArticleId IdType="pmc">PMC7902206</ArticleId><ArticleId IdType="pubmed">33662859</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Duarte &#xc1;, Rivera-Izquierdo M, Guerrero-Fern&#xe1;ndez de Alba I, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC Med. 2021;19:129. doi: 10.1186/S12916-021-02003-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12916-021-02003-7</ArticleId><ArticleId IdType="pmc">PMC8134820</ArticleId><ArticleId IdType="pubmed">34011359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:1&#x2013;12. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero Caballero S, Bilbao Fern&#xe1;ndez S. Persistencia del virus SARS-CoV-2 como causa etiol&#xf3;gica de la sintomatolog&#xed;a de larga duraci&#xf3;n en pacientes con COVID-19 persistente. Med Gen y Fam. 2021;10:85&#x2013;90. doi: 10.24038/MGYF.2021.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.24038/MGYF.2021.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dowds J, O&#x2019;Brien K, et al. Reply: the impact of acute illness severity on post-COVID-19 sequelae remains an unsettled question. Ann Am Thorac Soc. 2021;18:1754. doi: 10.1513/ANNALSATS.202103-303LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/ANNALSATS.202103-303LE</ArticleId><ArticleId IdType="pmc">PMC8522293</ArticleId><ArticleId IdType="pubmed">33730521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>